Case report for subcutaneous hematoma due to drug interaction between erlotinib and warfarin on an advanced lung cancer patient

Nan ZHAO,Qian XIANG,Qian-xin LIU,Yi-min CUI

DOI: https://doi.org/10.13699/j.cnki.1001-6821.2017.19.030

2017-01-01

Abstract:Objective To explore the role of clinical pharmacists involved in one case of subcutaneous hematoma induced by concomitant administration of erlotinib and warfarin on an advanced lung cancer patient.Methods An advanced lung cancer patient appered elevated international normalized ratio (INR) values and subcutaneous hematoma after concomitant administration of erlotinib and warfarin.Clinical pharmacist got the information of the adverse drug reaction and concomitant food and drug through detailed interrogation and analyzed metabolism characters and interaction mechanisms.Results and conclusion We concluded that both of diarrhea induced by erlotinib and potential warfarin interaction contributed the enhancement of warfarin efficacy and subcutaneous hematoma with elevated INR.We advised to adjust the warfarin dosage to i.5 mg,qd and monitor the INR closely.We explored the role and value of clinical pharmacist in the rational clinical drug usage and drug safety.